BridgeBio Pharma Inc logo

BridgeBio Pharma Inc

FRA:2CL (USA)  
€ 23.34 (-0.26%) Jul 1
At Loss
Market Cap:
€ 4.39B ($ 4.72B)
Enterprise V:
€ 5.52B ($ 5.93B)
Volume:
200.00
Avg Vol (2M):
161.00
Trade In:

Business Description

Description
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.
Name Current Vs Industry Vs History
Cash-To-Debt 0.3
Equity-to-Asset -1.24
Debt-to-Equity -1.65
Debt-to-EBITDA -3.8
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.41
Distress
Grey
Safe
Beneish M-Score 5.79
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 47.55
9-Day RSI 43.99
14-Day RSI 43.85
6-1 Month Momentum % -28.62
12-1 Month Momentum % 69.02

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.54
Quick Ratio 5.54
Cash Ratio 3.67
Days Payable 848.21

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -12.5
Shareholder Yield % -13.29

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 98.91
Operating Margin % -216.34
Net Margin % -246.24
FCF Margin % -278.21
ROA % -84.63
ROIC % -338.33
ROC (Joel Greenblatt) % -2138.82
ROCE % -89.47